Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ganetespib + paclitaxel + trastuzumab
- Development stage
- Phase 1
- Lead developer
- Madrigal Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination therapy consisting of three drugs—ganetespib (a heat shock protein 90 inhibitor), paclitaxel (a taxane chemotherapy agent), and trastuzumab (a monoclonal antibody targeting HER2). The combination has been investigated in clinical trials for the treatment of HER2-positive cancers, particularly metastatic breast cancer. Ganetespib inhibits HSP90, disrupting oncogenic client proteins; paclitaxel stabilizes microtubules to inhibit cell division; and trastuzumab binds to HER2 receptors to block signaling pathways that promote cancer cell growth[1][2].
- Other names
- ganetespib/paclitaxel/trastuzumabganetespib, paclitaxel, and trastuzumab
02
Targets
TUBB (Tubulin (alpha and beta subunits))ERBB2 (Erb-b2 receptor tyrosine kinase 2)HSP90 (Heat shock protein 90 chaperone complex)
Beyond the preview
Go deeper on ganetespib + paclitaxel + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ganetespib + paclitaxel + trastuzumab.